Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients
- 261 Downloads
KeywordsChronic Kidney Disease Imatinib Chronic Myeloid Leukemia Dasatinib Nilotinib
No specific funding was obtained to support the conduct of this study.
Compliance with ethical standards
Conflict of interest
All authors have no potential conflicts of interest to report.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.
- 1.Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. A systematic review and meta-analysis. JAMA Oncol. 2016;. doi: 10.1001/jamaoncol.2015.5932.Google Scholar